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Dithiol-based Compounds Maintain Expression of
Antioxidant Protein Peroxiredoxin 1 That Counteracts
Toxicity of Mutant Huntingtin*□
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Andrea Pitts‡1, Kyle Dailey‡1, Jordan T. Newington‡, Andrew Chien‡, Robert Arseneault‡, Tyler Cann‡,
Leslie M. Thompson§, and Robert C. Cumming‡2
From the ‡Department of Biology, University of Western Ontario, London, Ontario N6A 5B7, Canada and the §Department of
Biological Chemistry, School of Medicine, University of California Irvine, Irvine, California 92697
Background: Decreased antioxidant activity is implicated in neurodegenerative diseases, including Huntington disease
(HD).
Results: Mutant Huntingtin (mHtt) triggered loss of peroxiredoxin 1 (Prx1) expression in two nerve cell models. Dimercaptopropanol treatment attenuated both mHtt-induced toxicity and loss of Prx1 expression.
Conclusion: Chemical or genetic means of maintaining Prx1 expression counters mHtt toxicity.
Significance: Dithiol compounds may offer new treatment options for neurodegenerative diseases.
Mitochondrial dysfunction and elevated reactive oxygen species are strongly implicated in both aging and various neurodegenerative disorders, including Huntington disease (HD).
Because reactive oxygen species can promote the selective oxidation of protein cysteine sulfhydryl groups to disulfide bonds
we examined the spectrum of disulfide-bonded proteins that
were specifically altered in a HD context. Protein extracts from
PC12 cells overexpressing the amino-terminal fragment of the
Huntingtin (Htt) protein with either a nonpathogenic or pathogenic polyglutamine repeat (Htt-103Q) were resolved by redox
two-dimensional PAGE followed by mass spectrometry analysis. Several antioxidant proteins were identified that exhibited
changes in disulfide bonding unique to Htt-103Q expressing
cells. In particular, the antioxidant protein peroxiredoxin 1
(Prx1) exhibited both decreased expression and hyperoxidation
in response to mutant Htt expressed in either PC12 cells or
immortalized striatal cells exposed to 3-nitropropionic acid.
Ectopic expression of Prx1 in PC12 cells attenuated mutant Httinduced toxicity. In contrast, short hairpin RNA-mediated
knockdown of Prx1 potentiated mHtt toxicity. Furthermore,
treatment with the dithiol-based compounds dimercaptopropanol and dimercaptosuccinic acid suppressed toxicity in both HD
cell models, whereas monothiol compounds were relatively
ineffective. Dimercaptopropanol treatment also prevented
mutant Htt-induced loss of Prx1 expression in both cell models.
Our studies reveal for the first time that pathogenic Htt can
affect the expression and redox state of antioxidant proteins; an
event countered by specific dithiol-based compounds. These
findings should provide a catalyst to explore the use of dithiolbased drugs for the treatment of neurodegenerative diseases.

Huntington disease (HD)3 is an inherited adult onset neurodegenerative disorder characterized clinically by chorea, psychiatric disturbances and dementia, and pathologically by the
loss of striatal and cortical cell neurons. The disease is caused by
an expansion of a CAG trinucleotide repeat region in exon 1 of
the HTT gene, which encodes Huntingtin (Htt), a ubiquitously
expressed protein in the brain and peripheral tissues with an
uncertain molecular function (1). Individuals with HD have a
CAG expansion that results in enlargement of the polyglutamine (poly(Q)) tract within the N terminus of Htt to greater
than 36 residues. Longer poly(Q) stretches are associated with
earlier onset of HD and more severe disease symptoms (2). The
precise mechanism of HD pathophysiology is poorly defined
but evidence exists that multiple neurodegenerative pathways
are involved including mitochondrial impairment, oxidative
stress, transcriptional dysregulation, elevated apoptosis,
changes in intracellular transport, signaling dysfunction, and
altered protein interactions and activity (1).
Mutant Htt (mHtt) containing a poly(Q) repeat greater than
36 has a high predisposition to misfold and disrupt normal processes essential for cellular homeostasis (3). Among these,
mitochondrial dysfunction and elevated reactive oxygen species (ROS) production are strongly involved in HD progression
(4). Although mitochondria produce most of the cellular ATP,
they are also a major source of ROS production via electron
leakage from the respiratory chain (especially complexes I and
III). Several studies have shown that mHtt is found in association with the outer mitochondrial membrane in brain tissue
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from HD transgenic mice and in isolated mitochondria from
both lymphoblasts and postmortem brain tissue from HD
patients (5–7). In addition, isolated mitochondria from HD
mice exhibit decreased membrane potential, increased propensity to depolarize at lower calcium loads, and elevated sensitivity to calcium-induced cytochrome c release compared with
controls (5, 6). Transcription of peroxisome proliferator-activated receptor, a coactivator 1␣ (PGC1␣), a key transcriptional
co-activator that induces expression of genes that regulate
mitochondrial respiration and oxidative stress, is repressed in
mHtt-expressing neurons (8). Impaired mitochondrial respiration and ATP synthesis have been detected in postmortem
brain samples from HD patients and in various HD cell and
animal models (9). Collectively these findings strongly indicate
that perturbed mitochondrial function contributes to HD
pathogenesis.
Expression of mHtt in cultured non-neuronal or neuronal
cells has been shown to increase both ROS production and
toxicity, which can be rescued by treatment with the thiolbased antioxidants N-acetyl-L-cysteine (NAC) and glutathione
(GSH) (10, 11). Antioxidant treatment has also been shown to
reduce cytotoxicity associated with the expression of mHtt in
transgenic nematode and mouse models of HD (12, 13). However, the exact mechanism by which antioxidants counter
mHtt-induced toxicity is poorly defined.
Although ROS have traditionally been viewed as agents that
cause nonspecific damage to DNA, lipids, and proteins, recent
evidence has shown that ROS can act as second messengers and
selectively target proteins leading to a change in their activity or
function (14). The specificity of ROS-mediated signaling has
become an extremely active area of research over the last decade. Cysteine represents one of the major amino acids modified
by ROS in a highly selective and reversible manner. Oxidation
of protein cysteine sulfhydryl groups (Cys-SH) can lead to the
formation of covalent disulfide bonds (Cys-S-S-Cys) or higher
oxidized species such as sulfenic (Cys-SOH), sulfinic (CysSO2H), or sulfonic (Cys-SO3H) acids. Functional consequences
of Cys-SH oxidation include altered protein interactions, misfolding, catalytic inactivation, and decreased antioxidant
capacity (15). The specificity of ROS-mediated oxidation of cysteine residues within proteins that participate in a wide array of
cellular processes has made these proteins attractive targets for
therapeutic manipulation in diseases strongly linked to oxidative stress (16).
One of the best examples of redox regulation is found in the
peroxiredoxin family of proteins. Peroxiredoxins (Prxs) were
originally characterized as abundant antioxidant proteins that
contain a catalytic cysteine residue and detoxify hydrogen peroxide (H2O2), peroxynitrate, and a range of organic hydroperoxides using reducing equivalents supplied by the thioredoxin
system (17). However, recent studies have shown that Prxs participate in a wide array of cellular processes including neuronal
differentiation, cell signaling, molecular chaperoning, and
mitochondrial function in both a catalytic dependent and independent manner (18 –20). For example, Prxs are able to interact
with and inactivate protein kinases such as JNK, c-Abl, and
ASK1 in a redox-regulated manner (21).
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In an effort to determine the spectrum of disulfide-bonded
proteins (DSBP) that are altered in an HD context, and hence
potential targets of antioxidants, we resolved protein extracts
from PC12 cells that inducibly express exon 1 of the HTT gene
with either a 25 (nonpathogenic) or 103 (pathogenic) poly(Q)
repeat using a novel two-dimensional polyacrylamide gel electrophoresis (PAGE) technique to separate DSBP. Following
mass spectrometry analysis, a number of antioxidant proteins
were identified that displayed alterations in disulfide bonding
only in Htt-103Q expressing cells. In particular, Prx1 was
shown to exhibit a progressive decrease in expression and a
concomitant increase in protein sulfonylation following induction of mHtt expression. Testing of various thiol-based antioxidants revealed that dimercaptopropanol (DMP) and the structurally related compound dimercaptosuccinic acid (DMSA)
were specifically able to rescue mHtt-induced toxicity in PC12
cells, whereas monothiol reducing agents were relatively ineffective. In addition, DMP was able to protect against 3-nitropropionic acid-induced toxicity in a rodent HD striatal cell line.
DMP-mediated protection correlated with the maintenance of
Prx expression and suppression of Prx1 sulfonylation. These
novel findings suggest that dithiol-based compounds can selectively protect against mHtt-induced toxicity.

EXPERIMENTAL PROCEDURES
Reagents—Cell culture reagents including Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin, DMEM
without phenol red, and Dulbecco’s phosphate-buffered saline
(DPBS) were purchased from BioWhittaker (Walkersville,
MD). Fetal bovine serum (FBS) and horse serum were obtained
from PAA Laboratories Inc. (Etobicoke, ON, Canada). Bisbenzimide (Hoechst), poly-D-lysine, 3-(4,5-dimethlythiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT), 3-nitropriopionic
acid (3-NP), cysteamine (Cys), penacillamine (Pen), ␤-mercaptoethanol (␤-ME), dithiothreitol (DTT), NAC, glutathione-reduced ethyl ester (eeGSH), DMP, and DMSA were all purchased from Sigma. Opti-MEM media, Lipofectamine 2000,
and Mitotracker Red CM-H2XRos (Molecular Probes) was
purchased from Invitrogen.
Cell Lines—The PC12 HD nerve cell model was obtained
from Dr. Erik Schweitzer (UCLA) and maintained in DMEM
supplemented with 10% horse serum, 5% FBS, and 1% penicillin/streptomycin. These cells are stably transfected with a plasmid encoding the entire exon 1 of the HD gene with either a 25
(nonpathogenic) or 103 (pathogenic) poly(Q) repeat fused inframe to the coding sequence for the enhanced GFP at the carboxyl terminus (22) under control of an ecdysone-regulated
promoter. Transcription of the transgene was activated by the
addition of 2.5 M tebufenicide (an ecdysone analog) to the
culture medium. These cell lines exhibit extensive cell death
(⬎50%) 48 h after induction of Htt-103Q expression (22).
Immortalized striatal cell lines derived from a knock-in transgenic mouse containing homozygous htt loci with a humanized
exon 1 with either 7 (STHdhQ7) or 111 (STHdhQ11) poly(Q)
repeats (23) were obtained from the Corriel Institute (Camden,
NJ) and maintained in DMEM supplemented with 10% FBS and
1% penicillin/streptomycin at 33 °C in a humidified CO2 incuVOLUME 287 • NUMBER 27 • JUNE 29, 2012
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bator. Striatal cells were treated with 10 mM 3-nitropriopionic
acid for up to 48 h.
Determination of Mitochondrial Produced ROS—Mitochondrial ROS production was visualized using the fluorescent dye
Mitotracker Red CM-H2XRos (Invitrogen). PC12 Htt-25QGFP and Htt0103Q-GFP cells were seeded at 1 ⫻ 105 in polylysine-treated 6-well glass bottom dishes and induced the
following day with 2.5 M tebufenocide. At 24 and 48 h postinduction, medium was aspirated and cells were incubated in
DMEM containing 200 nM Mitotracker Red for 20 min at
37.5 °C in a humidified CO2 incubator. The medium was
removed and the cells were incubated for 5 min with PBS containing 10 g/ml of Hoechst stain to stain nuclei, followed by
two washes with PBS. Phenol Red-free DMEM was added to the
culture prior to visualization using a Zeiss AxioObserver A1
epifluorescent inverted microscope with a ⫻100 oil objective
and equipped with appropriate filters. Pictures were taken of
three random fields of view for each experiment using a Q
Imaging (Retiga 1300 monochrome 10-bit) camera and Q Capture software. Mitotracker Red fluorescence was quantified
with ImageJ software.
Protein Extract Preparation—For two-dimensional PAGE
and one-dimensional immunoblot experiments, PC12 cells
were seeded at 2.0 ⫻ 106 cells in 10-cm dishes and transgene
expression was induced 24 h after seeding with 2.5 M
tebufenocide. At various time points after induction, cells were
washed with cold phosphate-buffered saline (PBS), incubated
for 3 min with PBS containing 40 mM iodoacetamide to prevent
postlysis thiol-disulfide exchange, and scraped into 100 l of
Triton X-100 extraction buffer (50 mM Tris, pH 7.5, 1% Triton
X-100, 1 mM phenylmethanesulfonyl fluoride, 40 mM iodoacetamide). The cell suspension was rocked on ice for 20 min and
centrifuged at 15,000 ⫻ g for 10 min. Subsequently the supernatant (containing soluble proteins) was aliquoted and frozen
at ⫺80 °C. Striatal cell extracts were prepared by seeding striatal cells at 2.5 ⫻ 105 cells in 60-mm dishes and, following various treatments over the course of 48 h, were washed twice with
ice-cold PBS and harvested in 100 l of Triton X-100 extraction
buffer as described above. Protein content of cell extracts was
determined using the colorimetric Bio-Rad DC Protein Assay
Kit.
Redox Two-dimensional PAGE—Separation of DSBP by
redox two-dimensional PAGE was performed as described previously (16, 24). In brief, protein extracts (300 g) from Htt25Q-GFP or Htt-103Q-GFP expressing PC12 cells were
resolved for 5 h at constant current, under nonreducing conditions through a 1.5-mm thick, 12% polyacrylamide gel using a
Hoefer SE600 electrophoresis apparatus (San Francisco, CA).
Following electrophoresis in the first dimension, gel strips containing resolved proteins were excised and immersed in SDS
sample buffer (0.05 M Tris-HCl, pH 6.8, 5% glycerol, and 2%
SDS) containing 100 mM dithiothreitol (DTT) for 20 min at
room temperature to reduce disulfide bonds. Gel strips were
then washed with SDS-running buffer and immersed for 10 min
in SDS sample buffer containing 100 mM iodoacetamide. Each
gel strip was then applied horizontally to a second gel (1.5 mm
thick, 12% polyacrylamide) and run for 14 h at constant current
(10 mA/gel). After electrophoresis in the second dimension,
JUNE 29, 2012 • VOLUME 287 • NUMBER 27

gels were fixed in 50% methanol overnight and silver stained as
described previously (24).
MS Identification of Disulfide-linked Proteins—Gel spots
from redox two-dimensional gels were excised and in-gel
digested with trypsin using a MassPREP automated digester
station (PerkinElmer Life Sciences). Gel pieces were de-stained
of silver using 50 mM sodium thiosulfate 5-hydrate and 15 mM
potassium ferricyanide, followed by protein reduction using 10
mM DTT, alkylation using 55 mM iodoacetamide, and finally
digested with trypsin. Peptides were extracted using a solution
of 1% formic acid and 2% acetonitrile and lyophilized. Prior to
mass spectrometry analysis, dried peptide samples were re-dissolved in 10% acetonitrile and 0.1% TFA (trifluoroacetic acid).
Aliquots of digested samples were mixed with an equal volume
of MALDI matrix (␣-cyano-4-hydroxycinnamic acid, prepared
as 5 mg/ml in 6 mM ammonium phosphate monobasic, 50%
acetonitrile, 0.1% trifluoroacetic acid) at a 1:1 ratio. Mass spectrometry data were obtained using a 4700 Proteomics Analyzer,
MALDI TOF-TOF (Applied Biosystems, Foster City, CA). Data
acquisition and data processing were, respectively, done using
4000 Series Explorer and Data Explorer (both from Applied
Biosystems). The instrument is equipped with a 355-nm
Nd:YAG laser and run in the positive reflector mode. Monoisotopic masses were determined after internal calibration and
searched against the NCBInr rat protein data base using the
Mascot program and a mass tolerance of 25 ppm. Each mass
spectrum was collected as a sum of 1000 shots.
RNA Extraction and RT-PCR—RNA was extracted from
PC12 cells using TRIzol reagent (Invitrogen) following the
manufacturer’s protocol. Briefly, 1 g of total RNA was reverse
transcribed into cDNA using a 1st Strand cDNA Synthesis kit
for RT-PCR (Quanta BioSciences Inc). PCR was performed on a
Mastercycler thermocycler (Eppendorf) for 30 cycles for Prx1
and 27 cycles for GAPDH as a control. Each cycle included
denaturation at 94 °C for 20 s, annealing at 57 °C for 45 s, and
elongation at 72 °C for 45 s. The primers used for Prx1 were
forward, 5⬘-CCTGTAGCTCGACTCTGCTGATAG3⬘, reverse, 5⬘-GCGGCCAACAGGAAGATC-3⬘ and for GAPDH
were forward, 5⬘-CCTTCATTGACCTCAACTAC-3⬘, reverse,
5⬘-GGAAGGCCATGCCAGTGAGC-3⬘. The size of the PCR
products was determined by 1% agarose gel electrophoresis
with visualization by ethidium bromide staining.
Immunoblot Analysis—Triton X-100-soluble protein extracts (30 g) were resolved by 12% nonreducing and reducing
PAGE using a Hoefer SE600 electrophoresis apparatus.
Extracts resolved under reducing conditions were treated with
100 mM DTT and 2% ␤-ME and boiled for 5 min. Gels were
electroblotted onto Immobilon-P membrane (Millipore, Bedford, MA), blocked with 1% milk and 3% BSA (Sigma) in Trisbuffered saline with 0.5% Tween 20 (TBST). Membranes were
incubated with polyclonal rabbit antibodies against Prx1, sulfonylated Prx (Ab Frontier, South Korea), GFP (Sigma), and actin
(Cell Signaling) overnight. Following incubation, membranes
were washed with TBST and further hybridized with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad).
Detection was performed using Pierce ECL Western blotting
detection reagents (ThermoScientific) and visualized using a
ChemiDoc digital imaging system (Bio-Rad). Densitometric
JOURNAL OF BIOLOGICAL CHEMISTRY
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analysis was performed using Quantity One software (Bio-Rad).
Data presented are the average of three separate experiments.
Statistical analysis of densitometric averages was performed
using a one-way ANOVA followed by a post-hoc Tukey test.
Prx1 Expression Plasmids and Transfection Procedure—Expression constructs containing FLAG-tagged versions of both
wild type and cysteine mutant (C52S) Prx cDNAs were generously supplied by Dr. Hyunjung Ha (Chungbuk National University, Cheonju Korea). PC12-Htt-103Q-GFP cells were
seeded in 35-mm dishes at 3 ⫻ 105 cells/dish and co-transfected
with either pcDNA or FLAG-tagged Prx expression constructs
along with a mCherry Fluorescent Protein reporter plasmid at a
3:1 molar ratio for a total of 4 g of DNA per dish. Plasmid DNA
was mixed with 4 l of Lipofectamine 2000 (Invitrogen) in
Opti-MEM, added to PC12 cell cultures, and 6 h later the transfection medium was replaced with DMEM containing 10%
horse serum and 5% FBS. The following day transfected cells
were treated with 2.5 M tebufenocide to induce mHtt expression and at 48 and 72 h post-induction, cells were treated
Hoechst stain (10 g/ml) in PBS for 10 min, washed twice with
PBS, and trypsinized. Cells were counted using a hemocytometer by both light and epifluorescent microscopy. Cell viability
was assessed by comparing the average number of Hoeschtstained, mCherry-positive cells following tebufenocide induction versus cells transfected with the same plasmid but without
tebufenocide treatment. Mean cell viability ratios from three
separate experiments were analyzed using a one-way ANOVA
and post hoc Tukey test.
shRNA-mediated Knockdown of Prx1 Expression—HuSH29-mer shRNA pRS plasmids (Origene, Rockville, MD)
directed at rat Prx1 were used to knockdown endogenous Prx1
expression in PC12 Htt-103Q-GFP cells. Two shRNA containing expression cassettes, targeting different regions of Prx1
mRNA (Prx1-shRNA3, ATACCATCAAGCCTGATGTCAATAAGAGT; Prx1-shRNA4, TCAACTGCCAAGTGATTGGAGCTTCTGTG) were used. A scrambled (SCR) shRNA plasmid, which does not target any endogenous mRNA, was used as
a negative control. Prx1 and SCR shRNA plasmids were separately transfected into PC12 Htt-103Q-GFP cells followed by
selection with 2 g/ml of puromycin for 2 weeks. Cell viability
assays were performed as described below.
MTT and Trypan Blue Cell Viability Assays—For MTT cell
viability assays PC12 Htt-103Q-GFP cells were seeded in quadruplicate at 7,000 cells/well in 96-well plates (100 l total culture volume). Thiol-based compounds were added at various
concentrations (1, 5, 10, 50, 100, 500, and 1000 M) to 96-well
plates 24 h after seeding. One hour after compound exposure,
transgene expression was induced with 2.5 M tebufenocide.
48 h after induction of Htt-103Q-GFP expression 10 l of 2
mg/ml of MTT solution prepared in PBS was added to the culture media and incubated at 37 °C for 2 h. Media was thoroughly aspirated from the wells and the purple formazan product of MTT was released from cells by the addition of 100 l of
DMSO. Absorbance was measured at a test wavelength of 595
nm and reference wavelength of 655 nm using a Bio-Rad 3550
microplate reader.
Due to interference of 3-nitropropionic acid with the MTT
assay, cell viability in striatal cells was measured by trypan blue

22720 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 1. Expression of mHtt promotes an increase in mitochondrial
ROS. A, induction of mutant Huntingtin (HTT-103Q-GFP) in PC12 cells for 48 h
resulted in the formation of large aggregates (green) and increased mitochondrial ROS production (red), whereas induced expression of wild type HTT
(HTT-25Q-GFP) resulted in diffuse Htt expression and no increase in ROS production compared with uninduced cells. B, quantification of fluorescence
intensity revealed a significant (*, p ⬍ 0.01) increase in mitochondrial ROS
only in HTT-103Q-GFP expressing cells at 48 h. Cells were stained with Mitotracker Red CM-H2XRos and nuclei were stained with Hoescht (blue) followed
by visualization with fluorescence microscopy at ⫻400 magnification and
quantification with ImageJ software. Data represent the average ⫾ S.D. of
three independent experiments. Data were analyzed by a one-way ANOVA
followed by a Tukey test.

dye exclusion. In brief, STHdhQ7 and STHdhQ111 cells were
seeded in triplicate in 12-well plates at 2.5 ⫻ 104 cells/well and
treated with 10 mM 3-NP the following day. 24 h after 3-NP
treatment, cells were detached with 100 l of trypsin solution
and an equal volume of trypan blue was added. Cells were
counted using a hemocytometer and cell viability was determined by comparing the number of trypan blue excluding cells
in treated versus nontreated cells. Mean cell viability ratios from
three separate experiments were analyzed using a one-way
ANOVA and post hoc Tukey test.

RESULTS
Increased Mitochondrial ROS in mHtt Expressing PC12
Cells—We utilized a PC12 nerve cell model that has been stably
transfected with a plasmid encoding the entire exon 1 of the
VOLUME 287 • NUMBER 27 • JUNE 29, 2012
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FIGURE 2. Redox two-dimensional PAGE analysis of protein extracts from PC12 cells expressing nonpathogenic and pathogenic Htt. Triton X-100soluble proteins were isolated from PC12 cells following tebufenocide-induced expression of an amino-terminal Huntingtin (Htt) protein containing either a
nonpathogenic (25Q) or pathogenic (103Q) polyglutamine repeat. Following 2 days of induction, extracts were resolved by sequential nonreducing/reducing
SDS-PAGE (redox two-dimensional PAGE) and DSBP, spots in off-diagonal zones, were visualized by silver staining. PC12 cells expressing Htt-25Q (A) showed
little or no increase in DSBP following induced expression. In contrast, PC12 cells expressing Htt-103Q (B) displayed a pronounced increase in some DSBP (spots
1 and 4 – 6) and reduction in others (spots 2 and 3). The numbered spots were subsequently identified by mass spectrometery (see Table 1). The gels presented
are representative of three separate experiments.

TABLE 1
MS identification of DSBP altered in PC12 cells expressing mutant Huntingtin
Silver-stained DSBP that were altered in a mHtt-dependent manner in Fig. 2 were picked, in-gel digested with trypsin, and identified by MALDI-TOF mass spectrometry.
The relative change in disulfide bonding (1 increased, 2 decreased) of induced versus uninduced cells is indicated. A probability based MOWSE score greater than 50 was
considered significant.
Spot No.

Protein

Accession No.

Molecular mass

MOWSE score

Relative change

57
95
183
52
72
72
180
167

1
2
2
1
1
1
1
1

Function

kDa

1
2
3
4
5
6
7
8

Cu/Zn-SOD
Peroxiredoxin 2
Peroxiredoxin 1
Peroxiredoxin 4
Annexin-A2
␤-Actin
Calreticulin
Hypothetical

203,658
34,849,738
16,923,958
16,758,274
9,845,234
71,620
11,693,172
66,730,523

15.7
21.8
22.3
31
39
42
48.1
51.1

HTT gene with either a 25 (nonpathogenic) or 103 (pathogenic)
poly(Q) repeat fused in-frame to the coding sequence for the
enhanced GFP at the carboxyl terminus (22). Transcription of
the transgene is driven by an ecdysone-regulated promoter that
can be turned on by the addition of ecdysone or tebufenocide
(an ecdysone analog). Although several studies have shown eleJUNE 29, 2012 • VOLUME 287 • NUMBER 27

Antioxidant
Antioxidant
Antioxidant
Antioxidant
Vesicle trafficking
Cytoskeletal
Chaperone
Unknown

vated ROS formation in mHtt expressing mammalian cells (10,
11, 25), the exact site of ROS production is poorly defined. We
therefore examined mitochondrial derived ROS levels in Htt
expressing PC12 cells using MitoTracker Red CM-H2XROS, a
dye that is specifically targeted to mitochondria and only fluoresces in the presence of ROS (26). Induction of Htt-25Q-GFP
JOURNAL OF BIOLOGICAL CHEMISTRY
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expression in PC12 cells resulted in diffuse green fluorescence,
whereas Htt-103Q-GFP expressing cells exhibited large perinuclear protein aggregates (Fig. 1A). Elevated mitochondrial
ROS were detected at 2 days post-induction only in Htt-103QGFP expressing cells, whereas mitochondrial ROS levels
remained constant in either uninduced or induced Htt-25QGFP expressing cells (Fig. 1B). Therefore, expression of Htt
containing a pathogenic poly(Q) repeat results in elevated
mitochondrial ROS production.
mHtt Expression Promotes Changes in Protein Disulfide Bonding—To determine the spectrum of proteins that specifically
undergo changes in disulfide bonding in response to mHttinduced ROS production, cell lysates were analyzed by redox
two-dimensional PAGE. This technique, also known as diagonal electrophoresis, allows for the separation of disulfide-linked
proteins that appear as distinct spots in silver-stained gels
above and below a strong diagonal line (16). Lysates were processed from cells cultured for 48 h in either the presence of
tebufenocide or a vehicle control (DMSO). Redox two-dimensional PAGE analysis of protein extracts revealed a number of
proteins that exhibited both increased and decreased disulfide
bonding unique to Htt-103Q expressing cells (Fig. 2). Specifically, spots 2 and 3 exhibited a diminishment in disulfide bonding, whereas spots 1 and 4 – 8 displayed increased disulfide
bonding. In contrast, minimal alterations were observed in
DSBP following induction of nonpathogenic Htt-25Q expression. To ensure that the redox two-dimensional PAGE technique did not artificially induce disulfide bonding, protein
extracts were treated in both dimensions with the reducing
agent DTT. As expected, a clear diagonal line was revealed with
no spots in the off-diagonal zones (supplemental Fig. 1).
Identification of Proteins That Undergo Changes in Disulfide
Bonding in Response to mHtt Expression—Protein spots that
exhibited reproducible migration following redox two-dimensional PAGE were excised, in-gel digested with trypsin, and
identified by matrix-assisted laser desorption/ionization timeof-flight (MALDI-TOF) mass spectrometry. Analysis of the
protein spots revealed that half of the proteins identified (Table
1) were categorized as antioxidant proteins. Specifically the
peroxiredoxin (Prx) family of antioxidant proteins Prx1, -2, and
-4 were identified as proteins that exhibited changes in disulfide
bonding following mHtt expression. In addition, the antioxidant Cu/Zn-superoxide dismutase was shown to have
increased disulfide bonding. The four other proteins that were
identified (Table 1 and Fig. 2, spots 5–7) have various intracellular roles including molecular chaperoning, cytoskeletal
remodeling, and vesicular trafficking.
mHtt Promotes Decrease in Prx1 Expression—Prx1 is an
abundant intracellular protein within mammalian cells and
plays an essential role in protecting against oxidative stress (17).
In this study, Prx1 also exhibited the most robust decrease in
disulfide bonding following redox two-dimensional PAGE
analysis. Thus, we chose to examine Prx1 expression in the
PC12 cell model using one-dimensional immunoblot analysis
under both nonreducing and reducing conditions. Under normal cellular conditions, Prx1 predominately exists as a disulfide-linked homodimer. During its normal catalytic cycle, the
homodimeric form of Prx1 can be recycled back to its mono-
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FIGURE 3. Mutant Huntingtin promotes a decrease in peroxiredoxin 1
expression. A, cell lysates from PC12 cells treated with tebufenocide (⫹) to
induce expression of either nonpathogenic (Htt-25Q-GFP) or pathogenic (Htt103Q-GFP) forms of Htt were analyzed by immunoblotting with the indicated
antibodies. Cell extracts resolved under nonreducing conditions (top panel)
revealed that the disulfide-linked homodimeric form of Prx1 (spot 3 in Fig. 2)
was markedly decreased (arrow) after 2 and 3 days of mHtt induction. In
addition, mHtt expression promoted the accumulation of a potentially overoxidized monomeric form Prx1 (asterisk). Reprobing the above blot with an
anti-PrxSO2–3 antibody revealed that the monomeric Prx1 represented a sulfonylated species. Detection of transgene expression with an anti-GFP antibody revealed similar levels of Htt-25Q-GFP and Htt-103Q-GFP expression
throughout the course of induction. As a control, actin expression (bottom
panel) revealed equal loading for both uninduced and induced conditions.
Presented blots are representative of three separate experiments. B, RT-PCR
analysis of RNA extracted from PC12 treated with tebufenocide to induce
expression of Htt-103Q-GFP revealed dramatically decreased expression of
Prx1 by 48 h compared with uninduced controls. Data are representative of
three separate experiments.

meric form via thioredoxin (17). However, exposure to high
intracellular ROS can overoxidize the catalytic cysteine residue
of Prx1 to a sulfonic acid thereby rendering the protein unable
to form a disulfide bond (27). Immunoblot analysis of nonreduced protein extracts revealed a decrease in the homodimeric
disulfide-linked form of Prx1 at the 2- and 3-day time points
following induction of mHtt expression (Fig. 3A). Also apparent under nonreduced conditions was a monomeric form of
Prx1 (Fig. 3A). Blotting using an antibody that specifically recognizes sulfinic and sulfonic acid derivatives of Prxs (PrxSO2–3) revealed that the monomeric form of Prx1 was indeed a
hyperoxidized form of the protein (Fig. 3A). In contrast, Prx1
expression levels and the redox state remained unaltered in
cells expressing Htt-25Q. RT-PCR analysis revealed that levels
of the Prx1 mRNA transcript decreased dramatically 48 h after
induction of mHtt expression (Fig. 3B). To rule out the possibility that decreased Prx1 expression following mHtt induction
was simply due to nonspecific degradation of protein or mRNA
in dying cells, a live-dead cell assay was performed on the adherent cells used in expression analysis studies. As expected, an
overall decrease in the total number of cells was observed following induction of mHtt expression compared with nonVOLUME 287 • NUMBER 27 • JUNE 29, 2012
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FIGURE 4. Overexpression of wild type Prx1 suppresses mHtt-induced toxicity. A, FLAG-tagged Prx1 expression plasmids transfected into PC12–103Q-GFP
cells exhibited constitutive Prx1-FLAG expression (upper band) 48 and 72 h after tebufenocide (⫹)-induced mHtt expression, whereas endogenous Prx1 levels
(lower band) were decreased. Cell viability of PC12-Htt103Q cells transfected with the indicated plasmids was assessed after 48 (B) or 72 h (C) exposure to
tebufenocide to induce expression of mHtt. Data presented are the average of three independent experiments. Wild type Prx1 conferred significant protection
against mHtt-induced toxicity compared with the vector control (*, p ⬍ 0.05; **, p ⬍ 0.01; n ⫽ 3).

treated cells. However, under induced conditions the remaining adherent cells showed greater that 90% viability for up to 3
days (supplemental Fig. 2). These findings indicate that mHtt
specifically promotes the loss of Prx1 expression in PC12 cells.
Overexpression of Wild-type Prx1 Suppresses mHtt-induced
Toxicity—Because mHtt expression promotes the loss of
endogenous Prx1, it was asked if ectopic expression of Prx1 can
attenuate mHtt-induced toxicity. PC12 cells were transfected
with cDNA expression constructs that allow high level expression of FLAG-tagged versions of either wild type or a catalytically inactive version (C52S) of Prx1. Unlike endogenous Prx1,
levels of ectopically expressed wild type or mutant Prx1 were
maintained following induction of mHtt expression over the
course of 3 days (Fig. 4A). Moreover, cell viability analysis
revealed that elevated expression of wild type Prx1 attenuated
mHtt-induced toxicity at 48 and 72 h (Fig. 4, B and C). In contrast, mutant Prx1 exhibited only modest protection against
JUNE 29, 2012 • VOLUME 287 • NUMBER 27

mHtt-induced toxicity at 48 h (Fig. 4B) and had no protective
effect at 72 h (Fig. 4C). These findings indicate that maintenance of Prx1 levels can protect against toxicity initiated by
mHtt expression.
Dimercaptopropanol Suppresses mHtt-induced Toxicity,
Prx1 Hyperoxidation, and Loss of Prx1 Expression—Because
mHtt expression was shown to induce both loss of Prx1 expression and cell death in PC12 cells it was asked if thiol-based
antioxidants could counter these effects. Various thiol compounds were examined for their ability to counter mHtt toxicity including ␤-ME, DTT, cysteamine (Cys), NAC, reduced
eeGSH, DMP, DMSA, and penicillimine. DMP, and the related
compound DMSA, exhibited the most robust protection
(greater than 60% viability) against mHtt-induced toxicity in
PC12 cells (Fig. 5). In contrast, all the other thiol-based compounds either exhibited very modest protection (i.e. DTT) or
had no effect on cell viability at the concentrations tested.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. DMP treatment confers protection against mHtt-induced toxicity. PC12–103Q cells were treated with various thiol-based compounds
including ␤-mercaptoethanol (BME), DTT, cysteamine (Cys), NAC, eeGSH,
DMP, DMSA, and penicillimine (Pen) for 1 h before induction of mHtt expression with 2 M tebufenocide. After 48 h cell viability was measured by reduction of MTT. DMP elicited the highest degree of protection against mHttinduced toxicity.

Because DMP may have antioxidant effects, we examined mitochondrial ROS production in Htt-103Q expressing PC12 cells.
DMP treatment failed to attenuate mitochondrial ROS production in mHtt expressing cells (supplemental Fig. 3). Therefore,
DMP is unlikely to confer neuroprotection against mHtt toxicity by nonspecific antioxidant effects.
We next sought to determine whether the neuroprotective
properties of DMP also correlated with suppression of altered
disulfide bonding initiated by mHtt expression using redox
two-dimensional PAGE. Exposure of Htt-103Q expressing cells
to 100 M DMP, a concentration that is strongly neuroprotective, resulted in minimal changes in disulfide bonding following
induction of mHtt expression (Fig. 6A). In particular, the mHttinduced loss of disulfide-linked homodimers of peroxiredoxin 1
and 2 (spots 3 and 2, respectively, in Fig. 2) was completely
prevented by pretreatment with DMP. RT-PCR and immunoblot analysis revealed that DMP pretreatment maintained both
Prx1 mRNA and protein levels following induction of mHtt
expression (Fig. 6, B and C).
Recent studies have indicated that hyperoxidation (sulfonylation) of peroxiredoxins not only leads to their catalytic inactivation but also renders the proteins more susceptible to degradation (28, 29). Immunoblot analysis using an anti-Prx-SO2–3
antibody revealed that induction of mHtt expression resulted in
increased sulfonylation of Prx1 relative to total Prx1 levels (Fig.
6C). In contrast, DMP pretreatment prevented both mHtt-induced loss of Prx1 expression and sulfonylation.
Knockdown of Endogenous Prx1 Potentiates mHtt Toxicity—
To further determine the ability of Prx1 to attenuate mHtt toxicity, endogenous Prx1 expression was knocked down using
shRNAs specific to Prx1. Western blot analysis revealed an
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⬃65% knockdown in Prx1 protein levels in PC12-Htt-103Q
cells stably transfected with two shRNA expressing constructs
targeting different regions of the Prx1 mRNA compared with
control shRNA-transfected cells (Fig. 7A). A significant
decrease in viability was observed in Prx1-shRNA expressing
cells compared with the control cells following induction of
mHtt expression at both 24 and 48 h (Fig. 7, B and C). Furthermore, DMP treatment was unable to fully restore viability in
Prx1-shRNA expressing cells when compared with control
cells. These findings suggest that DMP-mediated suppression
of mHtt toxicity works, in part, by maintaining expression of
Prx1.
DMP Prevents 3-NP-induced Cell Death and Prx1 Hyperoxidation in a Striatal Cell Model of HD—To determine whether
DMP exerted similar protective effects in another cell model of
HD, we examined immortalized striatal cell lines derived from a
knock-in transgenic mouse in which either 7 glutamine repeats
(STHdHQ7) or 111 glutamine repeats (STHdHQ111) were
introduced into exon 1 of the mouse Htt gene (23). Treatment
with 3-NP, a mitochondrial complex II toxin, induces mitochondrial depolarization and cell death at significantly higher
levels in STHdhQ111 cells compared with STHdhQ7 cells (30).
Pre-treatment of STHdhQ111 cells with 10 M DMP before
3-NP exposure restored cell viability to a level comparable with
STHdhQ7 cells treated with 3-NP alone (Fig. 8A). Immunoblot
analysis revealed that 3-NP treatment promoted a dramatic loss
of Prx1 expression in STHdHQ111 cells but had little effect on
Prx1 levels in 3-NP-treated STHdHQ7 cells. In addition,
increased sulfonylation of Prx1 and another Prx isoform of ⬃22
kDa was observed in both STHdhQ7 and STHdhQ111 cells
following 3-NP treatment (Fig. 8B). However, the degree or
Prx1 oxidation, relative to total Prx1 levels, was higher in 3-NPtreated STHdhQ111 cells compared with STHdhQ7 cells (Fig.
8C). Moreover, DMP pre-treatment prevented Prx1 sulfonylation and the overall diminishment of Prx1 protein levels in
STHdhQ111 cells following 3-NP exposure. Therefore, DMP
treatment can prevent loss of Prx1 expression, Prx1 hyperoxidation, and cell death associated with either elevated mHtt
expression or exposure to a mitochondrial toxin that exacerbates HD pathology.

DISCUSSION
ROS have traditionally been viewed as deleterious molecules
that nonspecifically damage cellular macromolecules and contribute to various forms of neurodegeneration and aging. Elevated oxidation of DNA, protein, and lipids has frequently been
detected in postmortem brain tissue from patients afflicted
with various neurodegenerative diseases. Whether the elevation in oxidative damage associated with disease states is a
causal or correlative event has long been the subject of debate.
However, over the last decade numerous studies have shown
that ROS-mediated oxidation of cysteine residues acts as a key
signaling mechanism controlling multiple cellular processes
including protein phosphorylation, gene expression, chromatin
remodeling, protein turnover, molecular chaperoning, metabolism, autophagy, antioxidant defense, and mitochondrial
function in a specific and reversible manner (31). In fact, it is
now recognized that under physiological conditions transient
VOLUME 287 • NUMBER 27 • JUNE 29, 2012
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FIGURE 6. DMP treatment protects against mHtt-induced aberrant disulfide bonding and loss of Prx1 expression. A, redox two-dimensional PAGE
analysis of extracts from PC12-Htt-103Q cells treated with either DMP alone (control) or DMP followed by tebufenocide treatment to induce mHtt expression
(induced). DMP pre-treatment prevented the aberrant formation or loss of DSBP following mHtt expression. B, RT-PCR analysis of PC12-Htt-103Q cells either
treated with 100 M DMP alone or before Htt induction revealed that DMP treatment prevented loss of Prx1 expression even after 3 days of mHtt induction.
C, top, Western blot analysis of tebufenocide-treated PC12-Htt-103Q cells revealed that mHtt expression promoted increased sulfonylation and a concomitant
loss of Prx1 expression. DMP pre-treatment prevented mHtt-induced loss of Prx1 expression and suppressed sulfonylation. Bottom, quantification of Western
blots revealed a significantly lower ratio of sulfonylated Prx1 to total Prx1 in DMP-treated PC12 cells after induction of Htt-103Q, particularly at 72 h (*, p ⬍ 0.05,
n ⫽ 3).

low level generation of ROS appears to be essential to maintain
cellular homeostasis (32). However, relatively few studies have
attempted to detect oxidative modifications to cysteine residues in a disease context. One study revealed that glucose-6phosphate dehydrogenase, a key enzyme that generates
NADPH reducing equivalents in cells, is elevated in Alzheimer
disease brain along with a concomitant increase in reactive
JUNE 29, 2012 • VOLUME 287 • NUMBER 27

sulfhydryls in the neuronal cytoplasm (33). However, the identity of proteins with reactive sulfhydryl groups that are altered
in neurodegenerative diseases is poorly defined.
Here we show for the first time that increased expression of
pathogenic Htt promotes aberrant disulfide bonding in nerve
cell lines. In particular, mHtt expression promotes increased
disulfide bonding of the antioxidant proteins Cu/Zn-superoxJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. Knockdown of Prx1 potentiates mHtt-induced toxicity. A, PC12 Htt-103Q cells transfected with shRNA constructs targeting Prx1 mRNA exhibited
decreased Prx1 expression compared with control SCR-transfected cells. B, densitometric analysis of immunoblots revealed at least a 65% reduction of Prx1
expression in Prx1-shRNA stably transfected cells compared with SCR cells. Cells stably expressing Prx1-shRNA exhibited significantly decreased viability
following induction of mHtt expression compared with SCR control cells at both 24 (C) and 48 h (D). DMP treatment (100 M) was unable to fully rescue
mHtt-induced toxicity in Prx1-shRNA expressing cells compared with the scrambled control. Data presented are the average of three independent experiments (*, p ⬍ 0.05; **, p ⬍ 0.01).

ide dismutase 1 (SOD1) and Prx4 while decreasing disulfide
bonding of Prx1 and Prx2. SOD1 is a cytosolic protein responsible for the enzymatic conversion of the superoxide anion to
hydrogen peroxide. Prx1 and Prx2 are predominately cytosolic,
whereas Prx4 is a secreted peroxiredoxin isoform that is also
found in the endoplasmic reticulum. All three Prx isoforms
belong to the typical 2-cysteine family of peroxiredoxins that
undergo a catalytic cycle in which the N-terminal cysteine is
oxidized by H2O2 to a sulfenic acid that then reacts with the
C-terminal cysteine of another subunit to produce an intermolecular disulfide (17). This disulfide is then reduced by the Trx/
TrxR system, completing the catalytic cycle. During oxidative
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stress the sulfenic intermediate is hyperoxidized to a sulfinic
acid or a sulfonic acid, which is incapable of forming a disulfide
bond leading to inactivation of Prx peroxidase activity (27).
Oxidation of the catalytic cysteine to a sulfinic acid in Prxs 1– 4
is reversed by a reaction catalyzed by sulfiredoxin (34). However, overoxidation of all Prx isoforms to a sulfonic state is
irreversible.
In this study, we observed that mHtt expression promoted a
decrease in Prx1 expression and a concurrent increase in Prx1
sulfonylation. Hyperoxidation of Prxs has been show to render
these proteins susceptible to ubiquitin-mediated proteolysis
(28, 29). Therefore, mHtt may affect Prx1 expression at both
VOLUME 287 • NUMBER 27 • JUNE 29, 2012
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FIGURE 8. DMP treatment promotes viability and prevents loss of Prx1 expression in 3-NP-treated HD mouse striatal cells. A, DMP attenuated 3-NP
toxicity, following 24 h, in mouse striatal cells derived from mice with a knock-in of either 7 (STHdHQ7) or 111 (STHdHQ111) polyglutamine repeats. DMPtreated STHdHQ111 mouse striatal cells exhibited levels of viability similar to STHdHQ7 cells treated with 3-NP alone (*, p ⬍ 0.05, n ⫽ 3). B, Western blot analysis
of protein extracts from striatal cells revealed that 3-NP treatment promoted both loss of Prx1 expression and increased sulfonylation in STHdHQ111 cells but
not in STHdHQ7 cells. DMP pre-treatment prevented 3-NP-mediated loss of Prx1 expression and elevated sulfonylation. C, densitometric analysis of Western
blots revealed a significantly higher ratio (*, p ⬍ 0.05, n ⫽ 3) of sulfonylated Prx1 to total Prx1 following a 48-h 3-NP treatment in STHdHQ111 cells. In contrast,
the sulfonylated to total Prx1 ratio in DMP-treated STHdHQ111 cells was markedly lower following 3-NP exposure.

transcriptional and post-translational levels. In contrast, DMP
treatment prevented both mHtt-induced loss of Prx1 expression and increased sulfonylation. Prx1 expression is controlled
JUNE 29, 2012 • VOLUME 287 • NUMBER 27

by the transcription factor NF-E2 related factor-2 (Nrf2) (35).
Elevated ROS can promote oxidative modifications to Kelchlike ECH-associated protein 1 (Keap1), a negative regulator of
JOURNAL OF BIOLOGICAL CHEMISTRY
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Nrf2, leading to the stabilization and nuclear translocalization
of Nrf2 (36). Once in the nucleus, Nrf2 dimerizes with a small
Maf protein and the heterodimer then binds antioxidant
response element sequences within the promoters of antioxidant and phase II detoxifying genes. Besides activating transcription of Prx1, Nrf2 can also activate expression of sulfiredoxin, an enzyme that can reverse oxidation of Prx sulfinic
acids to sulfhydryl groups and various other antioxidant
enzymes (37). The observation that DMP exposure can partially
rescue mHtt-induced toxicity even when Prx1 expression is
knocked down (Fig. 7) suggests that this compound is likely to
alter expression of other neuroprotective genes. It is possible
that DMP may affect Nrf2 activation via a redox-dependent
mechanism leading to increased expression of Prx1, sulfiredoxin, and other antioxidant enzymes even in the presence of
mHtt. Future studies will evaluate this hypothesis.
We have previously shown that Prx1 levels are elevated and
overoxidized Prx2 isoforms predominate in Alzheimer diseased brain tissue (38). Overexpression of Prx1 alone can protect against amyloid-␤ toxicity in nerve cells. Furthermore,
amyloid-␤-resistant nerve cells up-regulate multiple Prx isoforms, in addition to the reductive enzymes required to maintain Prxs in an active state, thereby countering toxicity initiated
by amyloid-␤ exposure (38). A recent proteomic study showed
that the Prx isoforms 1, 2, and 6 are elevated in the striatum and
cortex of HD patients compared with unaffected individuals
(39). However, this study also detected the accumulation of
acidic (i.e. sulfonylated) forms of Prx1 and Prx6 in HD patients
as well. Collectively these findings indicate that maintenance of
Prxs at a high level and in an active state is key to ensuring
optimal neuronal cell survival in the presence of pathogenic
proteins associated with various neurodegenerative diseases.
The observation that oxidative damage to macromolecules is
increased in HD has spurred interest in evaluating the ability of
various antioxidants to attenuate mHtt-induced toxicity. A
number of studies have focused on the use of the molecule
Coenzyme Q10 (CoQ10) for the treatment of HD (40). CoQ10
functions in the inner membrane of mitochondria as an electron carrier from enzyme complex I and complex II to complex
III and can also act as a lipid soluble antioxidant, particularly in
its reduced form (ubiquinol, CoQ10H2). CoQ10 has been
shown to significantly increase survival and delay motor symptoms in transgenic HD mouse models (13). However, clinical
trials testing various formulations of CoQ10 in HD patients
have, so far, failed to fully recapitulate the positive effects of this
compound observed in animal models (41, 42). Whether
CoQ10 is able to completely target affected brain regions in HD
patients and either increase mitochondrial function or detoxify
elevated ROS is uncertain. The modest effect of this antioxidant
in HD patients may be related to its relative lack of specificity in
targeting oxidized intracellular targets. Although, CoQ10 can
detoxify lipid peroxides, it does so to varying extents in different
tissues and in a relatively nonselective manner. Furthermore, it
is now recognized that under physiological conditions, the
transient generation of ROS, within certain limits, appears to be
essential to maintain cellular homeostasis, whereas countering
low level ROS with broad-acting antioxidants can actually be
detrimental (32). For example, administration of antioxidants
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has been shown to inhibit autophagy and increase toxicity of
poly(Q) proteins (43). Therefore, identification of compounds
that possess good bioavailability and display some degree of
specificity in targeting oxidized proteins may be key factors for
the treatment of neurodegenerative diseases.
In this study we demonstrate for the first time that specific
dithiol-based compounds confer selective resistance to mHttinduced neurotoxicity. Although many commonly used monothiol antioxidants such as ␤-ME, NAC, and eeGSH were tested
in the mHtt-inducible PC12 cell model, only the dithiols DMP,
DMSA, and to a lesser extent DTT, showed neuroprotection.
This observation suggests that the protective effect of DMP
cannot fully be attributed to the nonspecific and widespread
reduction in intracellular disulfide bonding. DMP was previously shown in an unbiased blind screen of over 1000 FDA
approved compounds to be neuroprotective against mHtt toxicity in the same PC12 model used in this study (22). In addition,
DMP, also known as British anti-Lewisite (BAL), was shown to
reduce pathophysiological symptoms of HD and halt disease
progression in a long term study of two patients conducted in
1955 (44). At the time DMP was believed to work by chelating
metals but subsequent studies using the clinically more tolerable metal chelator penicillamine failed to alleviate HD clinical
symptoms (45). It is intriguing to note that penacillamine did
not confer protection against mHtt expression in PC12 cells
(Fig. 5) suggesting that the protective effect of DMP is unlikely
to be mediated by metal chelation. Although DMP exhibited
the highest level of protection against mHtt toxicity, it has poor
bioavailability properties and requires intramuscular injections. DMSA also exhibited protection in this study, albeit to a
lesser extent than DMP. DMSA is orally active and can cross the
blood-brain barrier (46, 47) making it an excellent candidate
drug for further testing as a therapy for HD. Moreover, the
structural relationship between the dithiols DMP and DMSA
and their strong neuroprotective effects in HD cell culture
models suggest that these molecules may be a good starting
point for further development of dithiol-based compounds to
treat HD and other neurodegenerative disorders.
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